Valuation : GENinCode Plc

Market Cap 7.15M 9.68M 8.32M 7.85M 13.37M 925M 13.49M 93.52M 35.99M 469M 36.34M 35.55M 1.49B P/E 2026 *
-1.36x
P/E 2027 * -
Enterprise Value 6.35M 8.6M 7.39M 6.97M 11.88M 822M 11.99M 83.07M 31.97M 417M 32.28M 31.57M 1.32B EV / Sales 2026 *
1.34x
EV / Sales 2027 * -
Free-Float
59.68%
Yield 2026 *
-
Yield 2027 * -
Current month-9.52%
1 month+11.76%
3 months+5.56%
6 months-15.56%
Current year-60.42%
1 week 0.9
Extreme 0.9
1.1
1 month 0.82
Extreme 0.825
1.25
Current year 0.75
Extreme 0.75
2.5
1 year 0.75
Extreme 0.75
5.5
3 years 0.75
Extreme 0.75
12.5
5 years 0.75
Extreme 0.75
43
10 years 0.75
Extreme 0.75
48
Manager TitleAgeSince
Chief Operating Officer 51 2018-09-05
Chief Executive Officer 62 2018-09-05
Director of Finance/CFO 57 2020-10-31
Director TitleAgeSince
Chairman 62 2018-09-05
Director/Board Member 51 2018-09-05
Director/Board Member 65 2020-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
5/6/26 Free

Founder

30,428,453 4.0407%
5/6/26 Free

Chairman

1,267,852 0.1684%
5/6/26 Free

Chief Financial Officer

13,523,757 1.7959%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-38.71%-92.24% 9.69M
-2.30%-1.25%+181.12%+371.62% 21.84B
-0.14%-5.73%-38.06%-22.24% 9.81B
-1.35%+5.00%+427.24%+40.16% 8.77B
+0.04%-5.06%-28.02% - 6.79B
-0.31%-0.58%+91.22%+51.19% 6.57B
-1.95%-4.25%-28.94%-22.04% 5.75B
-0.54%-4.12%-9.76%-19.88% 4.26B
-4.46%-8.28%+58.47%+71.78% 4.08B
+0.22%-0.80%-22.22%-30.00% 2.73B
Average -1.08%-2.18%+59.23%+38.70% 7.06B
Weighted average by Cap. -1.36%-1.47%+109.15%+134.54%

Financials

2026 *2027 *
Net sales 4.73M 6.4M 5.51M 5.19M 8.85M 612M 8.93M 61.86M 23.81M 310M 24.04M 23.51M 986M -
Net income -5.02M -6.79M -5.84M -5.51M -9.38M -649M -9.47M -65.61M -25.25M -329M -25.5M -24.94M -1.05B -
Net Debt -800K -1.08M -931K -878K -1.5M -103M -1.51M -10.46M -4.03M -52.48M -4.06M -3.98M -167M -
Logo GENinCode Plc
GENinCode Plc is a United Kingdom-based predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer. Its testing products include CARDIO inCode Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA Test. Its SITAB is an online Web portal, which provides health care practitioners with a systemized approach to request, record, process and report their clinical and genetic test results. Its CARDIO inCode Score is a genetic test for the evaluation of the coronary genetic load based on a polygenic risk score.
Employees
44
Date Price Change Volume
26-09-10 GBX 0.9500 0.00% 2,733,624
26-09-09 GBX 0.9500 0.00% 4,532,754
26-09-08 GBX 0.9500 0.00% 391,668
26-09-07 GBX 0.9500 -7.32% 2,894,231
26-09-04 GBX 1.025 +7.89% 3,273,306
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.009500GBP
Average target price
0.0750GBP
Spread / Average Target
+689.47%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GENI Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!